Top Oligo Synthesis Service Companies in Czech Republic

Content Menu

● Selection Criteria: How to Evaluate an Oligo Synthesis Supplier

● Supplier Comparison: Capacity, MOQ, and Certification

● 1. Gene Universal: A Flexible International Option for Research Teams

● 2. GENERI BIOTECH: An Established Czech Oligonucleotide Manufacturer

● 3. East Port Praha: A Local Ordering Channel for Oligos and Probes

● 4. Microsynth: A European DNA/RNA Synthesis Alternative

● 5. Integrated DNA Technologies: A Broad International Genomics Supplier

● Buyer's Guide: Qualifying a Long-Term Partner

>> Build a Complete Request for Quotation

>> Run a Representative Pilot Order

>> Watch for Substitution and Documentation Gaps

>> Insider Pitfall: Correct Mass Does Not Prove Complete Sequence Fidelity

>> Agree on Shipping and Change Control

● Conclusion

● Frequently Asked Questions

>> 1. How can we verify whether an ISO certificate is current and relevant?

>> 2. Can we compare two suppliers using their advertised purity percentages?

>> 3. What should a minimum-yield guarantee actually cover?

>> 4. How should we qualify an OEM supplier that outsources synthesis?

>> 5. Does a research-use oligo supplier qualify automatically for diagnostic purchasing?

● References

Choosing an Oligo Synthesis Service partner requires more than comparing prices per nucleotide. Procurement managers must assess sequence complexity, delivered yield, analytical documentation, production reliability, and the consequences of a failed batch.

The Czech Republic offers domestic oligonucleotide manufacturing alongside local procurement channels and access to international suppliers. Buyers should distinguish these categories: a Czech sales office or ordering platform does not necessarily mean synthesis takes place in a Czech facility.

For practical sourcing, Prague provides local laboratory supply channels, Hradec Králové hosts an established oligonucleotide manufacturer, and Brno adds molecular diagnostics expertise. These locations form a useful sourcing landscape, but they should not be presented as a quantified, nationally dominant oligo manufacturing cluster.

This guide compares five businesses for Czech procurement teams. It prioritizes traceability over promotional claims and explains what buyers should verify before establishing a long-term supply agreement.

Selection Criteria: How to Evaluate an Oligo Synthesis Supplier

This shortlist is a procurement framework, not a factory-audit report. Inclusion reflects publicly identifiable services and potential sourcing relevance.

Evaluate suppliers against six criteria:

1. Manufacturing identity: Confirm the legal seller, synthesis site, purification site, and any subcontractors.

2. Technical capability: Assess DNA/RNA availability, sequence-length limits, modifications, and difficult-sequence handling.

3. Quality control: Request identity testing, purity methods, delivered quantity, and lot-specific records.

4. Delivery reliability: Separate synthesis time from purification, release testing, dispatch, and transport.

5. Quality-system scope: Check certificate applicability to the actual manufacturing site and purchased service.

6. Commercial flexibility: Establish minimum orders, repeat-order pricing, confidentiality, and customization limits.

For conventional phosphoramidite synthesis, reagent quality, moisture control, coupling, capping, oxidation or sulfurization, and deprotection affect the final impurity profile.

Materials should be specified by intended application rather than a vague "premium grade." Standard primers, fluorescent probes, modified RNA, and research-use antisense oligonucleotides need different acceptance criteria.

CE marking and RoHS declarations should not be used as interchangeable proof of custom oligo quality. A finished diagnostic product's status does not automatically apply to a separately ordered research oligonucleotide. Environmental management should likewise be evaluated separately from sequence identity and purity.

Recent 2025 literature highlights advances in separation methods and enzymatic synthesis. For buyers, the practical lesson is to evaluate the analytical evidence behind a product—not simply whether its production technology sounds newer.

Supplier Comparison: Capacity, MOQ, and Certification

Published synthesis scale is not factory throughput. A 20 nmol ordering option describes a synthesis input scale, not guaranteed recovered material or daily production capacity.

Company	Location and sourcing role	Main purchasing fit	Capacity disclosure	MOQ or ordering scale	Certification status to verify
Gene Universal	US-headquartered international provider	Cost-conscious, customized research projects	No verified throughput figure used here	Obtain a project-specific quotation	Request applicable research-service documentation; no GMP claim
GENERI BIOTECH	Czech manufacturer, Hradec Králové	Custom DNA oligos and modified probes	Published scale options; no audited throughput figure	Standard options include 20, 40, 200 nmol and 1 μmol; restrictions apply	Publicly lists ISO 9001 and ISO 13485; verify current scope
East Port Praha	Czech procurement channel, Prague	Local ordering of oligos and probes	Underlying production capacity not established	Confirm sequence, format, and modification requirements	Verify the actual manufacturer’s documentation
Microsynth	Swiss-headquartered European manufacturer	DNA/RNA synthesis with related analytical services	No verified site-specific throughput figure used here	Product-dependent; request quotation	Request current certificates for the supplying site
Integrated DNA Technologies	US-founded international manufacturer	Broad custom nucleic acid and genomics purchasing	No current audited throughput figure used here	Product- and format-dependent	Verify the selected manufacturing site and product scope

International suppliers should confirm Czech delivery availability, invoicing arrangements, and the responsible production site before receiving an order.

1. Gene Universal: A Flexible International Option for Research Teams

Gene Universal is established in Delaware, United States. Its company profile reports operations across more than 100 countries and service to over 10,000 customers. The reviewed profile does not disclose its founding year.

Its broader positioning connects DNA/RNA services with protein and antibody research support. This can be useful when an oligonucleotide order forms part of a larger discovery workflow.

Gene Universal deserves consideration by smaller biotechnology businesses and research teams seeking cost-conscious, tailored service. However, buyers should compare actual quotations rather than assume it is always the lowest-cost option.

Its customer-focused positioning supports a discussion about sequence specifications, modifications, documentation, packaging, and repeat-order requirements. Communication efficiency should be tested through the quotation process: look for clear technical answers, documented assumptions, and realistic delivery commitments.

For OEM-style work, request written confirmation of confidentiality, custom labeling, specification-controlled repeat supply, and packaging options. These arrangements should not be assumed from general customization language.

Gene Universal does not provide GMP manufacturing, CDMO services, or IND submission support. Its role in this guide is fit-for-purpose research-grade materials and early discovery support—not therapeutic manufacturing.

2. GENERI BIOTECH: An Established Czech Oligonucleotide Manufacturer

Founded in 1995, GENERI BIOTECH developed from an oligonucleotide production business into a broader biotechnology company. Its history identifies modified oligos and probes as continuing areas of specialization.

Its published custom synthesis offering includes standard lengths of 2–99 bases and scales of 20 nmol, 40 nmol, 200 nmol, and 1 μmol. Unmodified oligos at the 20 nmol scale have a stated length restriction of up to 50 bases.

These concrete specifications make it a useful domestic candidate for Czech laboratories and businesses buying custom DNA oligonucleotides.

Quantities are reported using UV spectrophotometry, with nanomoles, optical units, and micrograms available. Standard purification removes salts and chemical impurities; buyers should separately specify stronger purification requirements when their application needs them.

For OEM-type procurement, discuss custom sequences, probe modifications, labeling, and recurring specifications. Do not assume private-label finished products or unrestricted RNA capability.

Its wider portfolio includes molecular diagnostics and life-science products. Buyers should distinguish those product certifications from the documentation applicable to a particular custom oligo order.

3. East Port Praha: A Local Ordering Channel for Oligos and Probes

East Port Praha operates from Prague and provides an online ordering route for oligonucleotides and dual-labeled probes. Its reviewed ordering page does not establish a founding year or an in-house synthesis facility.

Its main relevance is local procurement: Czech buyers can discuss sequence submissions, probe orders, and larger sequence lists through an established laboratory supply channel.

This model may suit organizations that prefer local-language communication and coordination alongside other laboratory purchases.

However, a local seller and an original manufacturer perform different roles. Ask who synthesizes the oligos, who releases each batch, and whose analytical records accompany delivery.

Customization should be evaluated at the underlying manufacturer level. Confirm available modifications, purification options, packaging, and confidentiality before describing the arrangement as OEM supply.

The reviewed evidence supports Czech-market laboratory sourcing. It does not justify claims about global manufacturing capacity or broad private-label capabilities.

4. Microsynth: A European DNA/RNA Synthesis Alternative

Microsynth was founded in 1989 as a spin-off of ETH Zurich and is headquartered in Switzerland. Its public company information describes DNA/RNA oligonucleotide synthesis and nucleic acid analysis for research and other applications.

Its combination of synthesis and analytical services may appeal to buyers seeking a broader nucleic acid service relationship.

For Czech procurement teams, it is an international alternative rather than a Czech factory. Confirm the supplying site, Czech delivery arrangements, and customs responsibilities where applicable.

Custom oligos should be quoted against exact sequence length, chemistry, modification position, purification, and recovered quantity.

For recurring or OEM-style procurement, discuss specification control and packaging directly. A broad custom synthesis portfolio does not automatically establish private-label finished-product services.

Its public positioning is European, with academic and commercial research relevance. Buyers should obtain site-specific quality documents instead of relying on group-level descriptions.

5. Integrated DNA Technologies: A Broad International Genomics Supplier

Integrated DNA Technologies, commonly known as IDT, was founded in 1987. Its portfolio includes custom DNA/RNA oligos, oligo pools, and other genomics products.

It is relevant to organizations managing diverse nucleic acid requirements under one purchasing framework. A broad portfolio can simplify vendor administration, although technical suitability remains product-specific.

For Czech orders, verify delivery eligibility, seller identity, dispatch location, and support arrangements. An international brand should not be described as a domestic Czech manufacturer.

Customization encompasses sequence-defined nucleic acid products. Buyers seeking OEM-style supply should separately negotiate recurring specifications, confidential sequence handling, packaging, and volume terms.

IDT serves an international research market. Historical production figures should not be treated as current capacity commitments: obtain a written delivery plan for the specific product and order volume.

Buyer's Guide: Qualifying a Long-Term Partner

Build a Complete Request for Quotation

Send every shortlisted supplier the same specification:

- Sequence written consistently in the 5′–3′ direction.

- DNA, RNA, or mixed chemistry.

- Exact modification names and positions.

- Purification method and analytical purity requirement.

- Minimum recovered quantity after purification.

- Identity-testing method and required documentation.

- Delivery format, concentration, packaging, and destination.

- Acceptable lead time and replacement conditions.

Distinguish synthesis scale from delivered yield. A larger starting scale does not guarantee a particular quantity after purification.

Run a Representative Pilot Order

Do not qualify a supplier using only an easy, short primer.

Include a routine sequence, a longer or compositionally challenging sequence, and a representative modified oligo. Compare analytical results, recovered quantity, functional performance, delivery accuracy, and responsiveness.

For recurring purchases, qualify a second independently manufactured batch. One successful order does not establish repeatability.

Watch for Substitution and Documentation Gaps

Common problems include ambiguous dye equivalents, unspecified purification, missing lot identifiers, and quantities quoted before purification losses.

Require written approval before any modification substitution. Dye identity and attachment chemistry can affect assay compatibility.

Avoid treating "HPLC purified" as a complete release specification. It describes a process; acceptance also requires an appropriate analytical method and agreed purity threshold.

Insider Pitfall: Correct Mass Does Not Prove Complete Sequence Fidelity

A matching molecular mass is important, but it does not universally establish nucleotide order or exclude every impurity.

Likewise, one chromatographic peak may conceal coeluting species, particularly in complex modified oligos.

For sequence-critical applications, discuss orthogonal characterization with the supplier. Depending on the chemistry, this may include additional separation methods, sequence-informative analysis, or application-specific testing.

The objective is proportionate evidence—not requesting the most expensive test for every routine primer.

Agree on Shipping and Change Control

Ask suppliers to justify shipping conditions for the actual chemistry and formulation. Do not impose one transport rule on all DNA, RNA, and modified oligos.

Confirm storage instructions, reconstitution guidance, buffer composition, customs documentation, and responsibility for delivery delays.

Long-term agreements should also define notification requirements for changes in manufacturing site, raw materials, analytical methods, or subcontractors.

Conclusion

For Czech procurement teams, GENERI BIOTECH offers a domestic manufacturing option, while East Port Praha provides a local ordering channel. Gene Universal, Microsynth, and IDT are international alternatives to evaluate against project requirements.

The strongest purchasing decision combines technical fit, transparent manufacturing responsibility, reproducible quality, and realistic delivery commitments.

Send Gene Universal a sequence list, modification requirements, purification specification, minimum recovered quantity, and delivery destination to request a research-use quotation. Compare it with domestic and European alternatives using the same qualification checklist.

Frequently Asked Questions

1. How can we verify whether an ISO certificate is current and relevant?

Check the legal entity, site address, standard, certificate number, scope, and validity dates. Verify authenticity with the issuing certification body where possible. An unexpired certificate is insufficient if its scope excludes the manufacturing site or purchased service.

2. Can we compare two suppliers using their advertised purity percentages?

Only when their methods and reporting conventions are comparable. Different chromatographic conditions can resolve impurities differently. Request the method, representative chromatogram, integration approach, and lot-specific acceptance criteria before interpreting identical percentages as equivalent quality.

3. What should a minimum-yield guarantee actually cover?

It should state the recovered quantity after the agreed purification, not merely the starting synthesis scale. Specify measurement method, units, concentration tolerance, delivery volume, and the remedy if the batch falls below the agreed minimum.

4. How should we qualify an OEM supplier that outsources synthesis?

Qualify both the seller and relevant manufacturing arrangements. Identify who controls specifications, releases batches, retains records, and approves changes. Require traceable documentation and advance notification of production-site or subcontractor changes. Outsourcing is not inherently unacceptable; undisclosed outsourcing is the concern.

5. Does a research-use oligo supplier qualify automatically for diagnostic purchasing?

No. Evaluate the intended use, applicable requirements, product documentation, and buyer responsibilities separately. Research-use labeling is not evidence that a product is suitable for diagnostic procedures. Do not transfer the status of a supplier's finished diagnostic kit to an unrelated custom oligo.

References

The following permitted scientific and regulatory sources support the technical purchasing guidance. Papers discussing therapeutic oligonucleotides are used for analytical principles, not to imply equivalent manufacturing capabilities among the listed suppliers.

1. [Recent advances in analytical separation techniques for therapeutic oligonucleotides]. Dérerová T., Vosáhlová Z., and Kalíková K. *Bioanalysis*, 2025; 17(18):1165–1180. Supports discussion of separation methods, complex impurity profiles, and chemistry-dependent analytical protocols. [pubmed.ncbi.nlm.nih]

2. [Recent Advances in Biocatalytic and Chemoenzymatic Synthesis of Oligonucleotides]. PubMed-indexed review, 2025. Provides recent context on enzyme engineering and alternative synthesis strategies; it is not a Czech market-size report. [pubmed.ncbi.nlm.nih]

3. [Therapeutic Oligonucleotides, Impurities, Degradants, and Their Characterization by Mass Spectrometry]. *Mass Spectrometry Reviews*, 2021; 40(2):75–109. DOI: 10.1002/mas.21615. Supports discussion of synthesis-related impurities, degradation, and mass-spectrometric characterization. [pubmed.ncbi.nlm.nih]

4. [Assay, Purity, and Impurity Profile of Phosphorothioate Oligonucleotide Therapeutics by Ion Pair-HPLC-MS]. PubMed-indexed analytical study. Supports the distinction between chromatographic purity, identity, and complex impurity assessment. [pubmed.ncbi.nlm.nih]

5. [Investigation of the Influence of Charge State and Collision Conditions on Oligonucleotide Analysis]. NIH-hosted full-text study, 2023. Discusses why accurate mass alone is insufficient for complete sequence characterization and the role of sequence-informative mass spectrometry. [pmc.ncbi.nlm.nih]

6. [Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only]. FDA guidance for industry and agency staff, November 2013. Supports the distinction between research-use products and diagnostic intended use. [fda]